Ann: Trading Halt, page-8

First 8 Last

Share
Profile

Follow
BigBullDollars

147 Posts.

26

01/11/24

17:00

Post #: 76423632
Share
Originally posted by benwex2: ↑

Offer Price:
Offer Price of A$0.10 per Security.
Discount:
47.4% discount to the last traded price on Thursday, 31 October 2024, A$0.19
45.1% discount to the 5-day VWAP A$0.182
45.1% discount to the 15-day VWAP A$0.182
Offer Details:
The Offeror seeks to raise approximately A$6 million by way of a Two Tranche Placement of up to 60 million shares (“Securities”) to sophisticated and professional investors (the "Offer" or the “Placement”). The Company reserves the right to accept oversubscriptions.
The Company’s major shareholder, Shenghe Resources (Singapore) Pte Ltd (“Shenghe Resources”), has committed to subscribe for approximately $1.2 million in the Placement. Shenghe Resources will not exceed 19.9% of the total number of fully paid ordinary shares on issue inclusive of the Placement Securities.
Shenghe Resources participation in the Placement will be issued subject to regulatory and shareholder approval in Tranche Two of the Placement.
It is the Company’s intention to also conduct a Share Purchase Plan (“SPP”) to seek to raise up to $2.0 million, although the terms and timing of the SPP have not yet been determined. Subject to the ASX Listing Rules and market circumstances at the relevant time it is intended that the SPP will be offered at the same price as the Placement and will enable existing eligible shareholders to apply for up to $30,000 worth of new shares in the Company. The final details of the SPP may vary from those disclosed above. Further details will be provided in due course.
Use of Proceeds:
Early and enabling works;
Finalisation of an EPCM agreement;
Land relocation and compensation payments;
Camp costs, local community & CSR programs;
Transaction costs associated with the Shenghe investment, development and funding agreement;
Peak and Mamba corporate costs and costs of the Offer.

Expand

10c?? Surely this is a joke for a 45% discount...
PEK Price at posting: 19.0¢ Sentiment: Hold Disclosure: Held
2 Upvote

1 Great analysis

Reply

Top Stories

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

First 8 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 27.8¢		Change -0.003(0.89%)		Mkt cap ! $96.83M

Open	High	Low	Value	Volume
28.0¢	28.5¢	27.5¢	$275.8K	982.3K

Buyers (Bids)

No.	Vol.	Price($)
6	413448	27.5¢

Sellers (Offers)

Price($)	Vol.	No.
28.0¢	96649	6

View Market Depth

No.	Vol.	Price($)
6	413448	0.275
6	414970	0.270
7	370192	0.265
7	1526383	0.260
4	333999	0.250

Price($)	Vol.	No.
0.280	96649	6
0.285	293500	3
0.290	24558	4
0.295	61893	2
0.300	153029	3

Last trade - 12.09pm 27/06/2025 (20 minute delay)

PEK (ASX) Chart

Ann: Trading Halt, page-8

Australia’s gas crisis is here – and dying coal plants aren’t helping

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Trading Halt, page-8

Top Stories

Australia’s gas crisis is here – and dying coal plants aren’t helping

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News